FDA calendar · August 2019 · built from SEC filings

PDUFA dates August 2019: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in August 2019. The FDA calendar also recorded 10 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in August 2019

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

August 2019: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
August 6, 2019Epzicom (abacavir sulfate; lamivudine)VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters
August 7, 2019Eysuvis (loteprednol etabonate)KALAComplete Response Letter—CRL issuedFDA Complete Response Letters
August 14, 2019WAKIX® (pitolisant)HRMYFDA approval—ApprovedopenFDA Drugs@FDA
August 14, 2019Pretomanid (pretomanid)VTRSFDA approval—ApprovedopenFDA Drugs@FDA
August 16, 2019RINVOQ® (upadacitinib)ABBVFDA approval—ApprovedopenFDA Drugs@FDA
August 16, 2019Inrebic (fedratinib hydrochloride)BMYFDA approval—ApprovedopenFDA Drugs@FDA
August 19, 2019Vyondys 53 (golodirsen)SRPTComplete Response Letter—CRL issuedFDA Complete Response Letters
August 28, 2019Harvoni (ledipasvir; sofosbuvir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
August 28, 2019Sovaldi® (sofosbuvir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
August 28, 2019nda210605VTRSComplete Response Letter—CRL issuedFDA Complete Response Letters

August 2019: dated readouts

No events in this view.

Questions

What PDUFA dates are in August 2019?

0 PDUFA dates fell in August 2019. The FDA calendar also recorded 10 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.